Skip to main content
. 2017 Jun 6;8(4):793–810. doi: 10.1007/s13300-017-0270-7

Fig. 3.

Fig. 3

HbA1c change from baseline (%) through week 52 in the omarigliptin/omarigliptin treatment groups by background AHA; filled circle sulfonylurea; open circle glinide; filled inverted triangle biguanide; filled triangle thiazolidinedione; filled square α-glucosidase inhibitor; based on the longitudinal data analysis model described in the “Statistical Analyses” section